Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1090101 | 0.80 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL1090578 | 0.80 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL1090762 | 0.77 | — | — | |
| SCHEMBL15845026 | 0.75 | SMN1; SMN2 (0.40) | MEN1KMT2AALDH1A1 | |
| SCHEMBL383047 | 0.72 | L3MBTL1 (0.39) | L3MBTL1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL383046 | 0.72 | L3MBTL1 (0.39) | L3MBTL1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2917196 | 0.71 | — | — | |
| SCHEMBL30619859 | 0.70 | — | — | |
| SCHEMBL28628583 | 0.70 | ALDH1A1 (0.41) | L3MBTL1MMP1MMP2ALDH1A1GAA | |
| SCHEMBL3230351 | 0.70 | ALDH1A1 (0.41) | L3MBTL1MMP1MMP2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290277-A1 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RES CO LTD (IN) | 2015-10-15 | — | — | US | disclosed |
| US-9095514-B2 | Pharmaceutical composition | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2015-08-04 | — | — | US | disclosed |
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8378099-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACUETICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110275597-A1 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2011-11-10 | — | — | US | disclosed |
| EP-2379077-A2 | PHARMACEUTICAL COMPOSITION | Sun Pharma Advanced Research Company Limited (IN) | 2011-10-26 | — | — | EP | disclosed |
| US-8003791-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| WO-2010089768-A2 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2010-08-12 | — | — | WO | disclosed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | disclosed |
| EP-0842164-A4 | CYCLIC AMIDES AND DERIVATIVES THEREOF | DURHAM PHARMACEUTICALS LLC (US) | 1998-10-07 | — | — | EP | disclosed |
| US-5780454-A | Boronic ester and acid compounds | PROSCRIPT, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0842164-A1 | CYCLIC AMIDES AND DERIVATIVES THEREOF | Durham Pharmaceuticals, LLC (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5703104-A | Cyclic amides and derivatives thereof | DURHAM PHARMACEUTICALS LLC (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1997003057-A1 | CYCLIC AMIDES AND DERIVATIVES THEREOF | DURHAM PHARMACEUTICALS, LLC (US) | 1997-01-30 | — | — | WO | disclosed |
| US-5559150-A | ANTICOAGULANT, ANTITUMOR, ANTIINFLAMMATORY | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275597-A1 | PHARMACEUTICAL COMPOSITION | BCAT2, TTR, BCAT1 | L3MBTL1 871/4885MEN1 1824/4885KMT2A 1734/4885 |
| US-20150290277-A1 | PHARMACEUTICAL COMPOSITION | BCAT2, TTR, BCAT1 | L3MBTL1 871/4885MEN1 1824/4885KMT2A 1734/4885 |
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | L3MBTL1 698/4885MEN1 2373/4885KMT2A 4259/4885 |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | L3MBTL1 698/4885MEN1 2373/4885KMT2A 4259/4885 |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | L3MBTL1 698/4885MEN1 2373/4885KMT2A 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.